Top Ten Equity Holdings and Exposures

Summary by AI ^BETAClose X

Polar Capital Global Healthcare Trust plc has disclosed its top ten equity holdings and sector and geographic exposure as of May 29, 2026. The top ten holdings, representing 52.2% of the portfolio, include Eli Lilly & Co at 9.5% and Roche Holding AG at 6.3%. Sector exposure is dominated by Pharmaceuticals (42.3%) and Biotechnology (25.4%), while geographic exposure is heavily weighted towards the United States (59.2%) and the United Kingdom (7.2%). The trust also reported a cash position of -8.4%.

Disclaimer*

Polar Capital Global Health Tst PLC

03 June 2026

3^rd June 2026

Polar Capital Global Healthcare Trust plc (the "Company")

Top Ten Equity Holdings and Sector and Geographic Exposure as at 29^th May 2026.

Polar Capital Global Healthcare Trust plc is pleased to announce that as at 29^th May 2026 the top ten equity holdings and the sector and geographic breakdown were as follows:

Top 10 Holdings	%
Eli Lilly & Co	9.5%
Roche Holding AG	6.3%
UnitedHealth Group	6.1%
AstraZeneca	5.5%
Thermo Fisher Scientific	4.9%
Teva Pharmaceutical Industries	4.8%
CVS Health Corp	4.4%
Cigna Corp	3.7%
Novo Nordisk A/S	3.6%
Merck KGaA	3.4%
Total	52.2%

Sector Exposure	%
Pharmaceuticals	42.3%
Biotechnology	25.4%
Healthcare Services	11.5%
Managed Healthcare	8.5%
Life Sciences Tools & Services	8.2%
Healthcare Equipment	7.7%
Healthcare Distributors	2.3%
Healthcare Supplies	1.6%
Healthcare Technology	0.9%
Healthcare Facilities	0.0%
Cash	-8.4%
Total	100.0%

Geographic Exposure	%
United States	59.2%
United Kingdom	7.2%
Denmark	6.5%
Switzerland	6.3%
Germany	5.6%
Israel	4.8%
Japan	3.6%
Netherlands	3.2%
India	3.0%
Ireland	2.3%
China	2.1%
Canada	1.7%
France	1.6%
Sweden	1.4%
Cash	-8.4%
Total	100.0%

The monthly factsheet will usually be available on the Company's website on the 10^th working day after the month end and includes a commentary by the investment manager. www.Polarcapitalhealthcaretrust.com

Neither the contents of the Company's website nor the contents of any website accessible from the hyperlinks on the Company's website (or any other website) is incorporated into or forms part of this announcement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END